Tercica Acromegaly Therapy Will Launch In Two Months
This article was originally published in The Pink Sheet Daily
Executive Summary
Based on firm's $100 million sales projections, Somatuline Depot likely will be priced at $25,000 per patient.
You may also be interested in...
Tercica Somatuline Autogel Launch Planned For 2007 Pending NDA Approval
Tercica’s partner, Ipsen, submitted an NDA for the acromegaly treatment Oct. 30.
Somatuline Autogel To Be Promoted By Tercica
Tercica gains the rights to the acromegaly treatment in the U.S. and Canada through a cross-licensing agreement with Ipsen, which receives European rights to Increlex.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.